Alexis C. Geppner, MLS, CTTS, PA-C, on IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy

Alexis C. Geppner, MLS, CTTS, PA-C, of The University of Texas MD Anderson Cancer Center, discusses important updates that advanced practitioners need to be aware of when treating patients with acute myeloid leukemia, including two key driver mutations (IDH1 and IDH2), the inhibitors ivosidenib and enasidenib, lower-intensity chemotherapy combinations, and the role of venetoclax and azacitidine.